BMS-986195

DRUG4 trials

Sponsors

Bristol-Myers Squibb

Conditions

Rheumatoid Arthritis

Phase 1

Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects

CompletedNCT02705989

Bristol-Myers SquibbRheumatoid Arthritis

Start: 2016-08-18End: 2017-08-16Updated: 2019-01-30

Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin

CompletedNCT03131973

Bristol-Myers SquibbRheumatoid Arthritis

Start: 2017-05-13End: 2017-11-10Updated: 2017-12-15

A Study of BMS-986195 in Healthy Male Subjects

CompletedNCT03245515

Bristol-Myers SquibbRheumatoid Arthritis

Start: 2017-08-15End: 2017-10-05Updated: 2018-01-05

The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

CompletedNCT03262740

Bristol-Myers SquibbRheumatoid Arthritis

Start: 2017-09-11End: 2018-01-30Updated: 2020-03-20

Related Papers

Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants

British Journal of Clinical Pharmacology2020-03-2126 citations